EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab

Marla C Dubinsky, Shervin Rabizadeh, John C Panetta iD, Elizabeth A Spencer, Annelie Everts-van der Wind, Thierry Dervieux

Pharmaceutics · 30.09.2023 · 15 (10) · 2408

DOI: 10.3390/pharmaceutics15102408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.09.2023. Verfasst von Marla C Dubinsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Medical Center, New York, NY 10029, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Prometheus laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in the treatment of Crohn’s disease (CD). We evaluated Clearance, another PF of PK origin, either alone or in combination with concentrations. They were evaluated from two cohorts, the first designed to receive standard dosing (n = 37), and the second designed to proactively target therapeutic IFX concentrations (n = 108). Concentrations were measured using homogeneous mobility shift assay. Clearance was estimated using the nonlinear mixed effects methods with Bayesian priors. C-reactive protein-based clinical remission (

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseclearanceinfliximabpharmacokineticspredictive factors

Autor:innen und Institutionen

  • Mount Sinai Medical Center, New York, NY 10029, USA.
  • Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
  • St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Prometheus Laboratories, San Diego, CA 92121, USA.

ORCID-Profile: John C Panetta

Förderung

  • NIDDK NIH HHS
  • Prometheus laboratories

Zitieren

APA

Dubinsky, M. C., Rabizadeh, S., Panetta, J. C., Spencer, E. A., Everts-van der Wind, A., & Dervieux, T. (2023). The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab. Pharmaceutics, 15(10), 2408. https://doi.org/10.3390/pharmaceutics15102408

Vancouver

Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, Everts-van der Wind A, Dervieux T. The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab. Pharmaceutics. 2023;15(10):2408. doi:10.3390/pharmaceutics15102408

BibTeX
@article{Dubinsky2023,
  author = {Dubinsky, Marla C and Rabizadeh, Shervin and Panetta, John C and Spencer, Elizabeth A and Everts-van der Wind, Annelie and Dervieux, Thierry},
  title = {The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2408},
  doi = {10.3390/pharmaceutics15102408}
}
Kostenlos starten →